Table 1 Participant disposition
319 Randomized | ||
|---|---|---|
Baseline: | 158 (100%) Assigned to snus | 161 (100%) Assigned to placebo |
158 (100%) Received assigned product, included in efficacy and safety analyses | 161 (100%) Received assigned product, included in efficacy and safety analyses | |
Week 1-24: | 26 (16%) Discontinued study | 23 (14%) Discontinued study |
132 (84%) Completed protocol follow-up | 138 (86%) Completed protocol follow-up | |
Week 24 visit: | 31 (20%) Failed to achieve protocol definition of smoking reduction | 29 (18%) Failed to achieve protocol definition of smoking reduction |
101 (64%) Continued in the study | 109 (68%) Continued in the study | |
Week 24-48: | 13 (8%) Discontinued study | 8 (5%) Discontinued study |
88 (56%) Completed protocol follow-up | 101 (63%) Completed protocol follow-up | |